TY  - JOUR
T1  - Endogenous glucocorticoids during skeletal ageing
AU  - Macfarlane, Eugenie 
AU  - Zhou, Hong
AU  - Seibel, Markus Joachim
Y1  - 2024///
JO  - Exploration of Endocrine and Metabolic Diseases
VL  - 1
IS  - 5
SP  - 191
EP  - 212
DO  - 10.37349/eemd.2024.00016
UR  - https://www.explorationpub.com/Journals/eemd/Article/101416
AB  - Stress hormones, namely glucocorticoids, have diverse actions throughout the body in regulating development, tissue metabolism, inflammation, circadian rhythms, and skeletal homeostasis. While endogenous glucocorticoid levels are important to support bodily homeostasis, chronically elevated levels can cause damage to tissues and drive diseases including bone loss (i.e., osteoporosis), myopathy (i.e., sarcopenia) and metabolic disturbances (i.e., glucose intolerance, diabetes, and abnormal fat accrual). There is substantial evidence that basal glucocorticoid levels increase during ageing while at the same time the amplitude of the diurnal variation in glucocorticoid secretion decreases. However, the significance of these changes for skeletal health is not well understood and has only recently been studied in more detail. Evidence from genetically modified mouse models indicates that changes in glucocorticoid signaling associated with ageing induce bone loss, sarcopenia and drive osteoarthritic joint disease. These studies provide important insights into the role of glucocorticoids in age-related skeletal diseases which will aid in the development of novel treatments especially needed for osteoarthritis which disproportionally affects the elderly.
ER  -